Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTY: Efanesoctocog Alfa in Haemophilia A
NCT06716814Phase 3Active, not recruiting
- Sponsor
- Sobi
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of efanesoctocog alfa in hemophilia A, sponsored by Sobi. Primary endpoints: Number of injections to treat a bleeding episode at 52 weeks, Total dose to treat a bleeding episode at 52 weeks and 7 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06716814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716814.